EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Henry Dickerson iD, Ahmad Diab iD, Othman Al Musaimi iD

International Journal of Molecular Sciences · 17.09.2024 · 25 (18) · 10008

DOI: 10.3390/ijms251810008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.09.2024. Verfasst von Henry Dickerson und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, ErbB Receptors, Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase inhibitors (TKIs) have emerged as a leading targeted cancer therapy, reducing the side effects often seen with non-targeted treatments, especially the damage to healthy cells. To tackle resistance, typically caused by epidermal growth factor receptor (EGFR) mutations, four generations of TKIs have been developed. Each generation has shown improved effectiveness and fewer side effects, resulting in better patient outcomes. For example, patients on gefitinib, a first-generation TKI, experienced a progression-free survival (PFS) of 10 months compared to 5 months with conventional chemotherapy. Second-generation TKI afatinib outperformed erlotinib and extended PFS to 11.1 months compared to 6.9 months with cisplatin. Third-generation TKIs further increased survival to 38.6 months, compared to 31.8 months with first-generation TKIs. This progress demonstrates the ability of newer TKIs to overcome resistance, particularly the T790M mutation, while reducing adverse effects. Ongoing research focuses on overcoming resistance from newer mutations like C797S to further improve patient survival. These developments highlight the significant progress in TKI therapy and the continued effort to refine cancer treatment. Recent research in South Korea shows that third-generation TKIs are ineffective against non-small cell lung cancer (NSCLC) with the C797S mutation. Several trials have started showing promising in vitro and in vivo results, but more trials are needed before clinical approval. This review underscores notable advancements in the field of EGFR TKIs, offering a comprehensive analysis of their mechanisms of action and the progression of various TKI generations in response to resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsErbB ReceptorsNeoplasmsHumansDrug Resistance, NeoplasmAntineoplastic AgentsMutationAnimalsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

NSCLCafatinibepidermal growth factor receptorsgefitinibtyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsErbB ReceptorsAntineoplastic AgentsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
  • Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.

ORCID-Profile: Henry Dickerson, Ahmad Diab, Othman Al Musaimi

Zitieren

APA

Dickerson, H., Diab, A., & Al Musaimi, O. (2024). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. International Journal of Molecular Sciences, 25(18), 10008. https://doi.org/10.3390/ijms251810008

Vancouver

Dickerson H, Diab A, Al Musaimi O. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. International Journal of Molecular Sciences. 2024;25(18):10008. doi:10.3390/ijms251810008

BibTeX
@article{Dickerson2024,
  author = {Dickerson, Henry and Diab, Ahmad and Al Musaimi, Othman},
  title = {Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {18},
  pages = {10008},
  doi = {10.3390/ijms251810008}
}
Kostenlos starten →